Fate Therapeutics (FATE) Change in Receivables (2018 - 2026)
Fate Therapeutics (FATE) reported Change in Receivables of -$212000.0 for Q1 2026, up 81.31% on a YoY basis from -$116930.0 in Q1 2025, and down 190.99% quarter-over-quarter from $233000.0 in Q4 2025.
Fate Therapeutics (FATE) Change in Receivables (2018 - 2026) Analysis & Trends
Fate Therapeutics has reported Change in Receivables for 8 years, with the latest figure at -$212000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 81.31% year-over-year to -$212000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.7 million (down 279.73% YoY), and the FY2025 full-year result was -$2.6 million, down 335.76% from the prior year.
- Change in Receivables for Q1 2026 stood at -$212000.0, down from $233000.0 in the prior quarter.
- The five-year high for Change in Receivables was $28.3 million in Q4 2022, with the low at -$25.0 million in Q1 2023.
- Historically, Change in Receivables has averaged -$504294.1 across 5 years, with a median of -$713000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 1970.11% — and 2023, when it sank 1373.2%.
- Fate Therapeutics' Change in Receivables stood at $28.3 million in 2022, then tumbled by 98.98% to $288000.0 in 2023, then tumbled by 304.17% to -$588000.0 in 2024, then soared by 139.63% to $233000.0 in 2025, then sank by 190.99% to -$212000.0 in 2026.
- The last three Change in Receivables figures came in at -$212000.0 (Q1 2026), $233000.0 (Q4 2025), and -$713000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -212,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212,000.00 |
| Mar 31, 2026 | -212,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Sep 30, 2025 | -713,000.00 |
| Jun 30, 2025 | -1.01 Mn |
| Jun 30, 2025 | -1.01 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Mar 31, 2025 | -1.13 Mn |
| Dec 31, 2024 | -588,000.00 |
| Dec 31, 2024 | -588,000.00 |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 190,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Mar 31, 2024 | -968,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |